Q4 2020 13F Holders as of 12/31/2020
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
197
-
Total 13F shares, excl. options
-
66M
-
Shares change
-
+1.68M
-
Total reported value, excl. options
-
$5.53B
-
Value change
-
+$204M
-
Put/Call ratio
-
0.2
-
Number of buys
-
112
-
Number of sells
-
-84
-
Price
-
$83.76
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q4 2020
232 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q4 2020.
Denali Therapeutics Inc. - Common Stock (DNLI) has 197 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 66M shares
of 145M outstanding shares and own 45.45% of the company stock.
Largest 10 shareholders include BAILLIE GIFFORD & CO (12.2M shares), VANGUARD GROUP INC (7.93M shares), PRICE T ROWE ASSOCIATES INC /MD/ (6.46M shares), BlackRock Inc. (6.38M shares), Temasek Holdings (Private) Ltd (4.41M shares), FMR LLC (3.51M shares), GILDER GAGNON HOWE & CO LLC (3.22M shares), STATE STREET CORP (2.07M shares), CREDIT SUISSE AG/ (1.4M shares), and Casdin Capital, LLC (1.31M shares).
This table shows the top 197 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.